Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

August 31, 2021

Conditions
Rosacea
Interventions
DRUG

AMG 334

30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)

Trial Locations (1)

Dk-2600

RECRUITING

Danish Headache Center, Glostrup Municipality

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Danish Headache Center

OTHER

collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

Herlev and Gentofte Hospital

OTHER

lead

Messoud Ashina

OTHER